Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and Irinotecan

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Outcome of Bevacizumab Therapy in Patients with Recurrent Glioblastoma Treated with Angiotensin System Inhibitors

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Systemic Immune Modulation in Gliomas: Prognostic Value of Plasma IL-6, YKL-40, and Genetic Variation in YKL-40

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Cell-free DNA in newly diagnosed patients with glioblastoma - a clinical prospective feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
We hypothesized that co-targeting the epidermal growth factor receptor (EGFR) and Src with the EGFR inhibitor gefitinib and the Src inhibitor AZD0530 would increase growth inhibition and impede migration. Cells overexpressing EGFR were more sensitive to gefitinib than cells expressing mutated EGFR or normal levels of wild-type EGFR. Furthermore, cells with mutated EGFR responded to low doses of gefitinib with increased proliferation. AZD0530 was an effective inhibitor of proliferation and migration, irrespective of EGFR status. These results suggest that co-targeting EGFR and Src might be a valuable treatment approach for malignancies associated with altered expression of EGFR, EGFRvIII, and/or Src.
Original languageEnglish
JournalCancer Investigation
Volume27
Issue number2
Pages (from-to)178-83
Number of pages6
ISSN0735-7907
DOIs
Publication statusPublished - 1 Feb 2009

ID: 31047978